Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafolecimab + sintilimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy consists of the PCSK9 inhibitor tafolecimab, the PD-1 inhibitor sintilimab, and chemotherapy (specifically nab-paclitaxel, docetaxel, or gemcitabine). It is being investigated as a second-line treatment for patients with advanced or metastatic driver gene-negative non-small cell lung cancer (NSCLC) who have progressed after first-line immunotherapy. The rationale for adding a PCSK9 inhibitor to immunotherapy in cancer involves the potential role of PCSK9 in regulating MHC-I expression on tumor cells; inhibiting PCSK9 may enhance tumor antigen presentation and improve the efficacy of PD-1 blockade. The regimen is currently being evaluated in a Phase II clinical trial led by Jinghui Wang at the Cancer Hospital of the Chinese Academy of Medical Sciences.
- Brand names
- SulinnoTyvyt
- Other names
- Tafolecimab and Sintilimab with Chemotherapy
02
Targets
TOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on tafolecimab + sintilimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafolecimab + sintilimab + chemotherapy.